"Nitriles" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Organic compounds containing the -CN radical. The concept is distinguished from CYANIDES, which denotes inorganic salts of HYDROGEN CYANIDE.
Descriptor ID |
D009570
|
MeSH Number(s) |
D02.626
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Nitriles".
Below are MeSH descriptors whose meaning is more specific than "Nitriles".
This graph shows the total number of publications written about "Nitriles" by people in this website by year, and whether "Nitriles" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 1 | 0 | 1 |
1995 | 2 | 1 | 3 |
1996 | 1 | 2 | 3 |
1997 | 3 | 2 | 5 |
1998 | 4 | 1 | 5 |
1999 | 3 | 1 | 4 |
2000 | 2 | 2 | 4 |
2001 | 7 | 2 | 9 |
2002 | 6 | 4 | 10 |
2003 | 10 | 8 | 18 |
2004 | 9 | 9 | 18 |
2005 | 7 | 8 | 15 |
2006 | 8 | 7 | 15 |
2007 | 5 | 6 | 11 |
2008 | 9 | 8 | 17 |
2009 | 0 | 4 | 4 |
2010 | 6 | 13 | 19 |
2011 | 8 | 20 | 28 |
2012 | 7 | 17 | 24 |
2013 | 9 | 24 | 33 |
2014 | 7 | 18 | 25 |
2015 | 9 | 23 | 32 |
2016 | 6 | 18 | 24 |
2017 | 7 | 24 | 31 |
2018 | 4 | 21 | 25 |
2019 | 5 | 15 | 20 |
2020 | 4 | 12 | 16 |
2021 | 10 | 9 | 19 |
2022 | 1 | 18 | 19 |
2023 | 1 | 17 | 18 |
2024 | 3 | 5 | 8 |
To return to the timeline,
click here.
Below are the most recent publications written about "Nitriles" by people in Profiles.
-
Enzalutamide induces cytotoxicity in desmoplastic small round cell tumor independent of the androgen receptor. Commun Biol. 2024 Apr 04; 7(1):411.
-
Phase 2 study of add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: final results. Blood Adv. 2024 Mar 26; 8(6):1515-1528.
-
The Impact of Circulating Tumor Cell HOXB13 RNA Detection in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide. Clin Cancer Res. 2024 Mar 15; 30(6):1152-1159.
-
Phase I Study of ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Progressing on Enzalutamide. Clin Cancer Res. 2024 Mar 15; 30(6):1111-1120.
-
Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor-Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2024 Mar 01; 10(3):362-371.
-
Clinical outcomes of patients with myelofibrosis after immediate transition to momelotinib from ruxolitinib. Haematologica. 2024 Feb 01; 109(2):676-681.
-
TBCRC 039: a phase II study of preoperative ruxolitinib with or without paclitaxel for triple-negative inflammatory breast cancer. Breast Cancer Res. 2024 01 31; 26(1):20.
-
Emerging data in COVID-19 create urgent challengers for health providers: Updates on COVID-19 vaccine and Paxlovid. J Natl Med Assoc. 2024 Apr; 116(2 Pt 1):174-179.
-
Cross-intolerance with bosutinib after prior tyrosine kinase inhibitors for Philadelphia chromosome-positive leukemia: long-term analysis of a phase I/II study. Haematologica. 2023 Dec 01; 108(12):3454-3459.
-
Bosutinib in Resistant and Intolerant Pediatric Patients With Chronic Phase Chronic Myeloid Leukemia: Results From the Phase I Part of Study ITCC054/COG AAML1921. J Clin Oncol. 2024 Mar 01; 42(7):821-831.